Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL

Blood

Volumn 118, Issue 2, 2011, Pages 446-455

  Hanash, Alan M ^a   Kappel, Lucy W ^a,b   Yim, Nury L ^a   Nejat, Rebecca A ^a   Goldberg, Gabrielle L ^a   Smith, Odette M ^a   Rao, Uttam K ^a   Dykstra, Lindsay ^a   Na, Il Kang ^a,c   Holland, Amanda M ^a,b   Dudakov, Jarrod A ^a   Liu, Chen ^d   Murphy, George F ^e   Leonard, Warren J ^f   Heller, Glenn ^a   Van Den Brink, Marcel R M ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOMODULATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 79960533396     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-294785     Document Type: Article

References (54)

1. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7(5):340-352. (Pubitemid 46674485)
2. van den Brink MR, Burakoff SJ. Cytolytic pathways in haematopoietic stem-cell transplantation. Nat Rev Immunol. 2002;2(4):273-281. (Pubitemid 37323227)
3. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000;95(9):2754-2759. (Pubitemid 30235880)
4. Petrovic A, Alpdogan O, Willis LM, et al. LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. Blood. 2004;103(4):1542-1547. (Pubitemid 38168676)
5. Reddy P. Pathophysiology of acute graft-versus-host disease. Hematol Oncol. 2003;21(4):149-161. (Pubitemid 38146266)
6. Pasquini M, Wang Z. Current use and outcome of hematopoietic stem cell transplantation, Part I: CIBMTR Summary Slides, 2009. CIBMTR Newslett. 2009;15(1):7-11.
7. Brandt K, Singh PB, Bulfone-Paus S, Ruckert R. Interleukin-21: a new modulator of immunity, infection, and cancer. Cytokine Growth Factor Rev. 2007;18(3-4):223-232. (Pubitemid 46891291)
8. Spolski R, Leonard WJ. The Yin and yang of interleukin-21 in allergy, autoimmunity and cancer. Curr Opin Immunol. 2008;20(3):295-301.
9. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol. 2008;26:57-79. (Pubitemid 351600371)
10. Herrin BR, Justement LB. Expression of the adaptor protein hematopoietic Src homology 2 is up-regulated in response to stimuli that promote survival and differentiation of B cells. J Immunol. 2006;176(7):4163-4172. (Pubitemid 44264396)
11. Ozaki K, Spolski R, Ettinger R, et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol. 2004;173(9):5361-5371. (Pubitemid 39392119)
12. Zhou L, Ivanov II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8(9):967-974. (Pubitemid 47300011)
13. Fantini MC, Rizzo A, Fina D, et al. IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur J Immunol. 2007;37(11):3155-3163. (Pubitemid 350131294)
14. Korn T, Bettelli E, Gao W, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature. 2007;448(7152):484-487. (Pubitemid 47123515)
15. Zeng R, Spolski R, Finkelstein SE, et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med. 2005;201(1):139-148. (Pubitemid 40130091)
16. Distler JH, Jungel A, Kowal-Bielecka O, et al. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum. 2005;52(3):856-864. (Pubitemid 40365109)
17. Datta S, Sarvetnick NE. IL-21 limits peripheral lymphocyte numbers through T cell homeostatic mechanisms. PLoS ONE. 2008;3(9):e3118.
18. Monteleone G, Monteleone I, Fina D, et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology. 2005;128(3):687-694. (Pubitemid 40585371)
19. Schmaltz C, Alpdogan O, Muriglan SJ, et al. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood. 2003;101(6):2440-2445. (Pubitemid 36302094)
20. Williamson E, Garside P, Bradley JA, Mowat AM. IL-12 is a central mediator of acute graft-versus-host disease in mice. J Immunol. 1996;157(2):689-699. (Pubitemid 26231372)
21. Abhyankar S, Gilliland DG, Ferrara JL. Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens. Transplantation. 1993;56(6):1518-1523. (Pubitemid 24018815)
22. Kappel LW, Goldberg GL, King CG, et al. IL-17 contributes to CD4-mediated graft-versus-host disease. Blood. 2009;113(4):945-952.
23. Das R, Chen X, Komorowski R, Hessner MJ, Drobyski WR. Interleukin-23 secretion by donor antigen-presenting cells is critical for organ-specific pathology in graft-versus-host disease. Blood. 2009;113(10):2352-2362.
24. Bucher C, Jasperson L, Vogtenhuber C, et al. IL-21 blockade reduces graft-versus-host-disease mortality by supporting inducible T regulatory cell generation. Blood. 2009;114(26):5375-5384.
25. Meguro A, Ozaki K, Oh I, et al. IL-21 is critical for GVHD in a mouse model. Bone Marrow Transplant. 2009;45(4):723-729.
26. Oh I, Ozaki K, Meguro A, et al. Altered effector CD4+ T cell function in IL-21R-/- CD4+ T cell-mediated graft-versus-host disease. J Immunol. 2010;185(3):1920-1926.
27. Hill GR, Olver SD, Kuns RD, et al. Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood. 2010;116(5):819-828.
28. Skak K, Kragh M, Hausman D, Smyth MJ, Sivakumar PV. Interleukin 21: combination strategies for cancer therapy. Nat Rev Drug Discov. 2008;7(3):231-240.
29. Jin H, Carrio R, Yu A, Malek TR. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J Immunol. 2004;173(1):657-665. (Pubitemid 38797396)
30. Meguro A, Ozaki K, Hatanaka K, et al. Lack of IL-21 signal attenuates graft-versus-leukemia effect in the absence of CD8 T-cells [published online ahead of print January 24, 2011]. Bone Marrow Transplant. doi:10.1038/bmt.2010. 342.
31. Choi J, Ritchey J, Prior JL, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease (GvHD) without sacrificing graft-versus-leukemia (GvL). Blood. 2010;116(1):129-139.
32. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9(9):1144-1150. (Pubitemid 37173698)
33. Jones SC, Murphy GF, Korngold R. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant. 2003;9(4):243-256. (Pubitemid 40045611)
34. Trenado A, Charlotte F, Fisson S, et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest. 2003;112(11):1688-1696. (Pubitemid 38063726)
35. Nadal E, Garin M, Kaeda J, Apperley J, Lechler R, Dazzi F. Increased frequencies of CD4+CD25high Tregs correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia. 2007;21(3):472-479.
36. Wang HY, Wang R-F. Regulatory T cells and cancer. Current Opinion in Immunology. 2007;19(2):217-223. (Pubitemid 46356965)
37. Blaschitz C, Raffatellu M. Th17 cytokines and the gut mucosal barrier. J Clin Immunol. 2010;30(2):196-203.
38. Salmi M, Jalkanen S. Lymphocyte homing to the gut: attraction, adhesion, and commitment. Immunol Rev. 2005;206:100-113. (Pubitemid 41105165)
39. Beilhack A, Schulz S, Baker J, et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood. 2005;106(3):1113-1122. (Pubitemid 41076462)
40. Panoskaltsis-Mortari A, Price A, Hermanson JR, et al. In vivo imaging of graft-versus-host-disease in mice. Blood. 2004;103(9):3590-3598. (Pubitemid 38525698)
41. Tanaka T, Ohtsuka Y, Yagita H, Shiratori Y, Omata M, Okumura K. Involvement of alpha 1 and alpha 4 integrins in gut mucosal injury of graft-versus-host disease. Int Immunol. 1995;7(8):1183-1189.
42. Kim TD, Terwey TH, Zakrzewski JL, et al. Organ-derived dendritic cells have differential effects on alloreactive T cells. Blood. 2008;111(5):2929-2940.
43. Waldman E, Lu SX, Hubbard VM, et al. Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. Blood. 2006;107(4):1703-1711. (Pubitemid 43242412)
44. Forster R, Schubel A, Breitfeld D, et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell. 1999;99(1):23-33. (Pubitemid 29468627)
45. Coghill JM, Carlson MJ, Panoskaltsis-Mortari A, et al. Separation of graft-versus-host disease from graft-versus-leukemia responses by targeting CC-chemokine receptor 7 on donor T cells. Blood. 2010;115(23):4914-4922.
46. Ferrari-Lacraz S, Chicheportiche R, Schneiter G, Molnarfi N, Villard J, Dayer J-M. IL-21 promotes survival and maintains a naive phenotype in human CD4+ T lymphocytes. Int Immunol. 2008;20(8):1009-1018.
47. Remberger M, Aschan J, Barkholt L, Tollemar J, Ringden O. Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clin Transplant. 2001;15(3):147-153. (Pubitemid 32487439)
48. Spolski R, Kim HP, Zhu W, Levy DE, Leonard WJ. IL-21 mediates suppressive effects via its induction of IL-10. J Immunol. 2009;182(5):2859-2867.
49. Piao WH, Jee YH, Liu RL, et al. IL-21 modulates CD4+ CD25+ regulatory T-cell homeostasis in experimental autoimmune encephalomyelitis. Scand J Immunol. 2008;67(1):37-46. (Pubitemid 350209584)
50. Frohlich A, Kisielow J, Schmitz I, et al. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science. 2009;324(5934):1576-1580.
51. Yi JS, Du M, Zajac AJ. A vital role for interleukin-21 in the control of a chronic viral infection. Science. 2009;324(5934):1572-1576.
52. Elsaesser H, Sauer K, Brooks DG. IL-21 is required to control chronic viral infection. Science. 2009;324(5934):1569-1572.
53. Reyes VE, Klimpel GR. Interferon alpha/beta synthesis during acute graft-versus-host disease. Transplantation. 1987;43(3):412-416. (Pubitemid 17044754)
54. Strengell M, Julkunen I, Matikainen S. IFN-alpha regulates IL-21 and IL-21R expression in human NK and T cells. J Leukoc Biol. 2004;76(2):416-422. (Pubitemid 39006956)